Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mycobacterial DNA binding protein 1 (MDP1) mediates gene regulation in Mycobacterium tuberculosis variant Bacillus Calmette-Guerin

ABSTRACT: To investigate the role of MDP1 in global transcription regulation, we established MDP1 conditional knockdown BCG using CRISPR/dCas9 system. Transcriptome profiling was then performed using data obtained from RNA-seq of two BCG MDP1 mutants compared to the vector control at three growth time points.

ORGANISM(S): Mycobacterium tuberculosis variant bovis

PROVIDER: GSE222247 | GEO | 2023/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Mycobacterium bovis Bacillus Calmette-Guerin (BCG) reprograms melanoma microenvironment to promote antitumor T cell responses

Project description:Intralesional therapy using Mycobacterium bovis Bacillus Calmette-Guérin (BCG) for cutaneous metastatic melanoma induces regression of injected, but also non-injected lesions. Tumor-associated macrophages (also known as M2) infiltrate solid tumors and impair antitumor immunity. Since macrophages play a pivotal role in both tumors and mycobacterial infections, we hypothesized BCG alters M2 to promote antitumor immunity. BCG-treated, in vitro-polarized M2 (M2-BCG) show dramatic transcriptional changes involving inflammation, immune cell recruitment, cross-talk and activation pathways. Mechanistic network analysis indicates potential for M2-BCG to improve IFN-γ responses, frequently used as a marker for successful antitumor immunity. Accordingly, we found an increased frequency of IFN-γ-producing CD4+ T cells responding to M2-BCG vs mock-treated M2 (p<0.05). Moreover, supernatant from M2-BCG increased the frequency of granzyme B-producing CD8+ tumor-infiltrating lymphocytes (TIL) responding to autologous melanoma cell lines (p<0.01). Comparing the transcriptome of injected vs uninjected lesions biopsied from IL-BCG patients showed immune function prevailing in injected lesions, with the most enriched pathways representing T cell activation mechanisms. In vitro BCG-infected tumor cells also stimulated IFN-γ production from HLA-A2-restricted syngeneic TIL from the same melanoma patient (p<0.05). Together, our data indicates BCG can promote an antitumor microenvironment in cutaneous metastatic melanoma.

2017-09-14 | GSE90748 | GEO

Distinct gene expression signatures comparing latent tuberculosis infection with different routes of Bacillus Calmette-Guérin vaccination

Project description:RNA-Seq was utilized to provide an unbiased assessment of systemic and mucosal immunity using blood cells from LTBI subjects and recipients of ID and oral (PO) BCG.

2023-12-01 | GSE223999 | GEO

Distinct gene expression signatures comparing latent tuberculosis infection with different routes of Bacillus Calmette-Guérin vaccination [blood]

Project description:RNA-Seq was utilized to provide an unbiased assessment of systemic and mucosal immunity using blood cells from LTBI subjects and recipients of ID and oral (PO) BCG.

2023-12-01 | GSE224055 | GEO

Mycobacterium tuberculosis variant bovis BCG strain:Bacillus Calmette-Guerin | isolate:M1_S49

Project description:Mycobacterium tuberculosis variant bovis BCG strain:Bacillus Calmette-Guerin | isolate:M1_S49 Genome sequencing and assembly

| PRJNA498011 | ENA

Immunopeptidomics of Bacillus Calmette-Guérin (BCG)-infected Thp-1 cells

Project description:We have immunoprecipitated MHC class-I and class-II complexes from THP-1 macrophages infected with BCG, eluted MHC-bound peptides and analysed them by liquid chromatography tandem mass spectrometry.

2020-05-26 | PXD015646 | Pride

A Mycobacterium tuberculosis Dormancy Antigen Differentiates Latently Infected Bacillus Calmette-Guerin-vaccinated Individuals.

Project description:IFN-γ release assays (IGRAs) are better indicators of Mycobacterium tuberculosis infection than the tuberculin skin test (TST) in Bacillus Calmette-Guérin (BCG)-vaccinated populations. However, IGRAs do not discriminate active and latent infections (LTBI) and no gold standard for LTBI diagnosis is available. Thus, since improved tests to diagnose M. tuberculosis infection are required, we assessed the efficacy of several M. tuberculosis latency antigens. BCG-vaccinated healthy donors (HD) and tuberculosis (TB) patients were recruited. QuantiFERON-TB Gold In-Tube, TST and clinical data were used to differentiate LTBI. IFN-γ production against CFP-10, ESAT-6, Rv2624c, Rv2626c and Rv2628 antigens was tested in peripheral blood mononuclear cells. LTBI subjects secreted significantly higher IFN-γ levels against Rv2626c than HD. Additionally, Rv2626c peptide pools to which only LTBI responded were identified, and their cumulative IFN-γ response improved LTBI discrimination. Interestingly, whole blood stimulation with Rv2626c allowed the discrimination between active and latent infections, since TB patients did not secrete IFN-γ against Rv2626c, in contrast to CFP-10 + ESAT-6 stimulation that induced IFN-γ response from both LTBI and TB patients. ROC analysis confirmed that Rv2626c discriminated LTBI from HD and TB patients. Therefore, since only LTBI recognizes specific epitopes from Rv2626c, this antigen could improve LTBI diagnosis, even in BCG-vaccinated people.

| S-EPMC4563115 | biostudies-literature

Mycobacterium tuberculosis variant bovis BCG

Project description:Mycobacterium bovis BCG Genome sequencing

| PRJNA266372 | ENA

Mycobacterium tuberculosis produces small noncoding RNAs that support mycobacterial survival in infected cells [RNA-seq]

Project description:The purpose of this study was to identify the role of sncRNA-1 using a gain of function approach. It was overexpressed in 3 clones and Total RNA was sequenced in 3 clones that had either the ctl vector or the sncRNA-1 vector. Differentially expressed genes were analyzed.

2020-03-03 | GSE146227 | GEO

Mycobacterium tuberculosis variant bovis BCG

Project description:Mycobacterium tuberculosis variant bovis BCG Genome sequencing

| PRJNA256163 | ENA

Mycobacterium tuberculosis variant bovis BCG

Project description:Mycobacterium tuberculosis variant bovis BCG Genome sequencing

| PRJNA159787 | ENA